News & Updates

The combination regimen comprising sotorasib and panitumumab demonstrates a trend towards an improvement in overall survival (OS) compared with investigator’s choice of therapy among patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) who had progressed on systemic therapy, according to the OS analysis of the CodeBreak 300 trial presented at ASCO 2024.

Topical sildenafil cream appears to deliver promising outcomes for premenopausal women with sexual arousal disorder with or without concomitant decreased sexual desire, with increased arousal and reduced sexual distress, according to the results of an exploratory post hoc efficacy analysis of a phase IIb trial.

Outcomes of allogeneic hematopoietic cell transplant (alloHCT) do not differ in patients who underwent either one or two sets of busulfan therapeutic drug monitoring (TDM) sampling, reports a study.

Identifying hypersensitivity reactions to anticancer chemotherapy and monoclonal antibodies may help clinicians improve management of patients with oncological diseases, suggests a study.

Treatment with vonoprazan, a potassium competitive acid blocker (P-CAB), successfully starts and sustains the healing of Los Angeles (LA) grade C/D esophagitis as compared with proton pump inhibitor (PPI) and has moderate short- and long-term safety, according to a study. On the other hand, other P-CAB therapies need more evidence to prove their advantages.

In the treatment of critically ill patients with sepsis, continuous infusion of β-lactam antibiotics does not appear to significantly reduce 90-day mortality compared with intermittent infusions, according to the results of an open-label BLING III trial.

Densiron, a heavier-than-water endotamponade agent, may be used in the treatment of primary rhegmatogenous retinal detachment (RRD) in eyes with predominantly inferior retinal pathology and proliferative vitreoretinopathy (PVR) grade C, as shown by its higher anatomic success rates and improved visual outcomes relative to conventional light silicone oil (LSO), suggests a study.

The investigational dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor survodutide helps reduce the histological activity of metabolic dysfunction-associated steatohepatitis (MASH) as well as improve fibrosis, according to the phase II 1404-0043 trial.